Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Inventory-to-Revenue : 3.92 (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Clarus Therapeutics Holdings's Average Total Inventories for the quarter that ended in Jun. 2022 was $15.87 Mil. Clarus Therapeutics Holdings's Revenue for the three months ended in Jun. 2022 was $4.05 Mil. Clarus Therapeutics Holdings's Inventory-to-Revenue for the quarter that ended in Jun. 2022 was 3.92.

Clarus Therapeutics Holdings's Inventory-to-Revenue for the quarter that ended in Jun. 2022 increased from Mar. 2022 (3.63) to Mar. 2022 (3.92)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Clarus Therapeutics Holdings's Days Inventory for the three months ended in Jun. 2022 was 1,248.20.

Inventory Turnover measures how fast the company turns over its inventory within a year. Clarus Therapeutics Holdings's Inventory Turnover for the quarter that ended in Jun. 2022 was 0.07.

Clarus Therapeutics Holdings Inventory-to-Revenue Historical Data

The historical data trend for Clarus Therapeutics Holdings's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings Inventory-to-Revenue Chart

Clarus Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

Inventory-to-Revenue

0.92

0.72

Clarus Therapeutics Holdings Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Inventory-to-Revenue	Get a 7-Day Free Trial			-	2.91	2.93	3.63	3.92

Competitive Comparison of Clarus Therapeutics Holdings's Inventory-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarus Therapeutics Holdings's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Clarus Therapeutics Holdings's Inventory-to-Revenue falls into.

Clarus Therapeutics Holdings Inventory-to-Revenue Calculation

Clarus Therapeutics Holdings's Inventory-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

	Inventory-to-Revenue (A: Dec. 2021 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2020 )	+	Total Inventories (A: Dec. 2021 ))	/	count )	/	Revenue (A: Dec. 2021 )
=	( (5.857	+	14.214)	/	2 )	/	13.957
=	10.0355					/	13.957
=	0.72

Clarus Therapeutics Holdings's Inventory-to-Revenue for the quarter that ended in Jun. 2022 is calculated as

	Inventory-to-Revenue (Q: Jun. 2022 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Mar. 2022 )	+	Total Inventories (Q: Jun. 2022 ))	/	count )	/	Revenue (Q: Jun. 2022 )
=	( (14.93	+	16.805)	/	2 )	/	4.05
=	15.8675					/	4.05
=	3.92

Clarus Therapeutics Holdings (OTCPK:CRXTQ) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Clarus Therapeutics Holdings's Days Inventory for the three months ended in Jun. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2022 )	/	Cost of Goods Sold (Q: Jun. 2022 )	*	Days in Period
	=	15.8675	/	1.16	*	365 / 4
	=	1,248.20

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Clarus Therapeutics Holdings's Inventory Turnover for the quarter that ended in Jun. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2022 )	/	Average Total Inventories (Q: Jun. 2022 )
	=	1.16	/	15.8675
	=	0.07

Clarus Therapeutics Holdings Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062

Website

https://www.clarustherapeutics.com

Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.

Executives

Thomas Mcnerney & Partners Lp	10 percent owner	45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr	director	C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory	director	C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley	director, officer: Chief Executive Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson	officer: Chief Financial Officer	1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger	officer: Chief Commercial Officer	CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne	officer: Chief Administrative Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd	10 percent owner	DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p.	10 percent owner	45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402